(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.15%) $78.60
(-1.50%) $2.16
(-0.10%) $2 328.90
(-0.39%) $27.51
(0.34%) $968.20
(0.09%) $0.929
(0.21%) $10.85
(0.08%) $0.797
(0.00%) $91.35
Quarter results tomorrow
(amc 2024-05-08)
Expected move: +/- 6.12%
1.59% $ 15.95
Live Chart Being Loaded With Signals
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy...
Stats | |
---|---|
Volumen de hoy | 289 187 |
Volumen promedio | 772 466 |
Capitalización de mercado | 1.45B |
EPS | $0 ( 2024-02-21 ) |
Próxima fecha de ganancias | ( $-0.970 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.84 |
ATR14 | $0.0220 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Jarrett Jennifer | Sell | 11 551 | Common Stock |
2024-03-18 | Jarrett Jennifer | Sell | 12 153 | Common Stock |
2024-03-18 | Jarrett Jennifer | Sell | 1 296 | Common Stock |
2024-02-26 | Jarrett Jennifer | Sell | 24 555 | Common Stock |
2024-02-27 | Jarrett Jennifer | Sell | 34 070 | Common Stock |
INSIDER POWER |
---|
95.54 |
Last 100 transactions |
Buy: 19 279 293 | Sell: 529 920 |
Volumen Correlación
Arcus Biosciences Inc Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Arcus Biosciences Inc Correlación - Moneda/Commodity
Arcus Biosciences Inc Finanzas
Annual | 2023 |
Ingresos: | $117.00M |
Beneficio Bruto: | $101.00M (86.32 %) |
EPS: | $-4.15 |
FY | 2023 |
Ingresos: | $117.00M |
Beneficio Bruto: | $101.00M (86.32 %) |
EPS: | $-4.15 |
FY | 2022 |
Ingresos: | $112.00M |
Beneficio Bruto: | $98.00M (87.50 %) |
EPS: | $-3.71 |
FY | 2021 |
Ingresos: | $382.88M |
Beneficio Bruto: | $382.88M (100.00 %) |
EPS: | $0.964 |
Financial Reports:
No articles found.
Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico